Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

150 results about "Endotoxin removal" patented technology

Endotoxin Removal Kit (Maxi) - This DNA purification kit is used for rapid removal of endotoxins from up to 1 mg of previously purified DNA. It can reduce endotoxin levels to 0.1 EU/µg DNA or less and can effectively remove endotoxins in as little as 30 minutes.

Omeprazole sodium freeze-dried powder injection and preparation method thereof

ActiveCN101703483AReduce the risk of adverse reactionsComply with the requirements of human intravenous injectionPowder deliveryOrganic active ingredientsOmeprazole SodiumFiltration
The invention discloses an omeprazole sodium freeze-dried powder injection and a preparation method thereof. The omeprazole sodium freeze-dried powder injection contains an active ingredient, namely, omeprazole sodium monohydrate, and auxiliary materials, namely, calcium disodium edetate and sodium hydroxide. The preparation method of the omeprazole sodium freeze-dried powder injection is characterized by comprising the following steps: weighing the calcium disodium edetate of prescription amount and dissolving the calcium disodium edetate in water for injection, stirring, dissolving, and regulating pH value to 10.0-12.0 by using 10% of sodium hydroxide solution; weighing omeprazole sodium of the prescription amount and adding the omeprazole sodium in the mixture, stirring at room temperature for dissolution, supplementing and adding the water for injection to full amount; adding active carbon, stirring at room temperature for decoloration and endotoxin removal, conducting rough filtration to remove carbon firstly, and then conducting refining filtration by using a filter membrane of 0.22 Mum; taking refining filtrate to test intermediate, conducting encapsulation after meeting requirements; and freeze-drying and unboxing, thus obtaining the omeprazole sodium freeze-dried powder injection. The freeze-drying technology of the omeprazole sodium freeze-dried powder injection takes temperature below minus 40 DEG C as pre-freezing temperature; after pre-freezing for at least two hours, sublimation is started, wherein the sublimation temperature is 5-12 DEG C, the sublimation time is over 14 hours; and then drying is conducted for over 2 hours at the temperature of 20-35 DEG C. Unboxing is carried out after a stopper is added and a cover is put in place, thus obtaining the finished product of the omeprazole sodium freeze-dried powder injection.
Owner:HAINAN LEVTEC PHARMA

Potential preparation method for highly-efficient recombinant HIV-1 CRF07-BC gp140 immunogen

The invention discloses a potential preparation method for a highly-efficient recombinant HIV-1 CRF07-BC gp140 immunogen. The immunogen is designed based on the structure of HIV-1 envelope protein crystals which have been published internationally and obtained in our lab. The specific method uses an overlap extension PCR technology to obtain gp140 gene segments, and comprises the steps that target genes are cloned into an eukaryotic expression vector pMT, endotoxin is removed through extraction of a large amount of plasmids, the gp140 gene segments and resistance screening plasmids pCoBlast are co-transfected into drosophila melanogaster Schneider2 (S2) cells together, blasticidin (Blasticidin S) is used for positive clone screening, S2 cell lines for stably and efficiently secreting and expressing gp140 are screened, and after enlarged cultivation and through two steps of purification of nickel column affinity chromatography and gel filtration chromatography, the gp140 with high purity can be obtained. A series of biochemical and biophysical technologies indicate that the gp140 is uniform in polymeric states, and high in antigenic reactivity, and is quite fittingly used as the immunogen for the research and the development of AIDS subunit vaccines or multivalent combined vaccines.
Owner:NANKAI UNIV

Purification method of human glucagon like peptide-1 (hGLP-1) analogue fusion proteins

The invention provides a purification method of human glucagon like peptide-1 (hGLP-1) analogue fusion proteins (including dulaglutide). The purification method includes the step that a three-step chromatography method is adopted for purification, specifically, a sample is firstly subjected to a coarse purification step of Protein A affinity chromatography so as to effectively remove impurities such as HCP and endotoxin and maintain the high objective protein yield; and then anion exchange chromatography and hydrophobic chromatography are used for further fine purification so as to effectivelyremove charge isomers, residual HCP and other trace impurities in the sample, the content of all the impurities is controlled within the administration safety range, and the high objective protein yield and activity are maintained. According to the purification method, during separation and purification of an objective protein, good reproducibility and stability are achieved, and the purificationmethod is suitable for downstream purification process linear amplification of the hGLP-1 analogue fusion proteins so as to be used for production and preparation of drugs for treating type 2 diabetes or slimming drugs.
Owner:CHENGDU JINKAI BIOTECH CO LTD

Adsorbent used for blood or plasma perfusion to remove endotoxin and preparation method thereof

The invention relates to an adsorbent used for blood or plasma perfusion to remove endotoxin (lipopolysaccharide) and a preparation method thereof. The adsorbent is a nano-composite structure adsorbent. Large-aperture polyvinyl alcohol serves as a carrier, amino (ammonio) carbon nanotubes (single-walled or multi-walled) serve as a ligand, epichlorohydrin or glutaraldehyde, etc. serves as a crosslinking agent, and the ligand and the carrier microspheres undergo covalent coupling to obtain the adsorbent. The adsorbent is simple to prepare, and an endotoxin adsorption property is good. The adsorbent is suitable for blood or plasma perfusion to remove excessive endotoxin in the body of a patient.
Owner:NANKAI UNIV

Method for removing bacterial endotoxin in protein solution

The invention discloses a method for removing bacterial endotoxin in a protein solution. The method comprises the following steps of S1, preparing aluminum hydroxide gel, namely adding 2mol / L sodium hydroxide into 4.5% of aluminum chloride solution to obtain a solution with the pH value of 7.0-7.5, reacting at the temperature of 2-8 DEG C for 1-2 hours, and centrifugally collecting gel at the speed of 4000rpm; and S2, removing bacterial endotoxin in the protein solution, adding the aluminum hydroxide gel prepared in the step S1 into the protein solution, stirring at the temperature of 4 DEG C and the speed of 100rpm for 1.5-2.5 hours, and centrifugally collecting at the speed of 4000rpm to obtain a supernatant solution without endotoxin. According to the method, electrostatic adsorption is mainly used as the way of adsorbing proteins by using the aluminum hydroxide gel, the adsorption of aluminum hydroxide to the proteins can be reduced or avoided when phosphate radicals and high-concentration NaCl (contained in a PB buffer solution) exist, and 99% of bacterial endotoxin can be removed by using the buffer solution.
Owner:CHENGDU OLYMVAX BIOPHARM

Factor c for treating gram-negative bacterial infection

Recombinant fragments of Factor C are disclosed. These proteins and peptides show great potency in recognizing, binding to, neutralizing and removing endotoxin. These molecules can thus be used for anti-microbial, anti-endotoxin, and anti-sepsis therapy. SSCrFCES is a 38 kDa protein representing the LPS-binding domain of Factor C. The ability of SSCrFCES to bind lipid A was analyzed using an ELISA-based assay as well as surface plasmon resonance. Surface plasmon resonance similarly carried out for SSCrFC-sushi-1,2,3-GFP, SSCrFC-sushi-1GFP, and SSCrFC-sushi-3GFP confirmed their superior affinity for endotoxin. The 50% endotoxin-neutralizing concentration of SSCrFCES against 200 EU of endotoxin is 0.069 μM, suggesting that SSCrFCES is an effective inhibitor of LAL coagulation cascade. Although partially attenuated by human serum, as low as 1 μM of SSCrFCES inhibits the LPS-induced secretion of hTNF-α and hIL-8 by THP-1 and human pheripheral blood mononuclear cells with a potency more superior than polymyxin B. SSCrFCES is non-cytotoxic, with a clearance rate of 4.7 ml / minute. The LD90 of SSCrFCES for LPS lethality in mice is achieved at 2 μM. These results demonstrate the endotoxin-neutralizing capability of SSCrFCES in vitro and in vivo, as well as its potential for use in the treatment of endotoxin-induced septic shock. Also embodied in this application is the use of the sushi peptides and their mutant derivatives as potent antimicrobials.
Owner:NAT UNIV OF SINGAPORE

Materials and methods for removing endotoxins from protein preparations

A method includes (i) adding allantoin in a supersaturating amount to a protein preparation including a desired protein and at least one endotoxin as a contaminant, (ii) removing solids after the adding step to provide a sample for further purification by void exclusion chromatography on a packed particle bed of electropositive particles in a column, the packed particle bed having an interparticle volume, (iii) applying a sample volume to the packed particle bed, wherein the electropositive particles support void exclusion chromatography, and wherein the sample volume is not greater than the interparticle volume, and (iv) eluting a purified sample including the desired protein and a reduced amount of the endotoxin. The method is optionally carried out with only the allantoin treatment or only the void exclusion chromatography.
Owner:AGENCY FOR SCI TECH & RES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products